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medication assessment criteria and prioritisation
of topics for improvement
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Abstract
Background: Addressing the problem of preventable drug related morbidity (PDRM) in primary care is a challenge
for health care systems internationally. The increasing implementation of clinical information systems in the UK and
internationally provide new opportunities to systematically identify patients at risk of PDRM for targeted medication
review. The objectives of this study were (1) to develop a set of explicit medication assessment criteria to identify
patients with sub-optimally effective or high-risk medication use from electronic medical records and (2) to identify
medication use topics that are perceived by UK primary care clinicians to be priorities for quality and safety
improvement initiatives.
Methods: For objective (1), a 2-round consensus process based on the RAND/UCLA Appropriateness Method
(RAM) was conducted, in which candidate criteria were identified from the literature and scored by a panel of 10
experts for ‘appropriateness’ and ‘necessity’. A set of final criteria was generated from candidates accepted at each
level. For objective (2), thematically related final criteria were clustered into ‘topics’, from which a panel of 26 UK
primary care clinicians identified priorities for quality improvement in a 2-round Delphi exercise.
Results: (1) The RAM process yielded a final set of 176 medication assessment criteria organised under the
domains ‘quality’ and ‘safety’, each classified as targeting ‘appropriate/necessary to do’ (quality) or ‘inappropriate/
necessary to avoid’ (safety) medication use. Fifty-two final ‘quality’ assessment criteria target patients with unmet
indications, sub-optimal selection or intensity of beneficial drug treatments. A total of 124 ‘safety’ assessment
criteria target patients with unmet needs for risk-mitigating agents, high-risk drug selection, excessive dose or
duration, inconsistent monitoring or dosing instructions. (2) The UK Delphi panel identified 11 (23%) of 47 scored
topics as ‘high priority’ for quality improvement initiatives in primary care.
Conclusions: The developed criteria set complements existing medication assessment instruments in that it is not
limited to the elderly, can be implemented in electronic data sets and focuses on drug groups and conditions
implicated in common and/or severe PDRM in primary care. Identified priorities for quality and safety improvement
can guide the selection of targets for initiatives to address the PDRM problem in primary care.
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morbidity
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Background
Systematic reviews have demonstrated deficits in the
quality and safety of medication use in primary care to
an extent sufficient to constitute a public health threat.
Three to four percent of all unplanned hospital admis-
sions are due to preventable drug related morbidity
(PDRM), with the majority attributed to high-risk pre-
scribing and inconsistent monitoring [1-4]. Antiplatelets,
diuretics, non-steroidal anti-inflammatory drugs
(NSAIDs) and anticoagulants account for almost half of
preventable drug-related admissions to hospital, with
opioid analgesics, beta-blockers, drugs affecting the
renin angiotensin system and anti-diabetic agents also
frequently implicated [1]. In addition, safety alerts have
been issued for drugs less commonly implicated in
PDRM but associated with preventable deaths, such as
prescribing and monitoring of methotrexate [5] and use
of antipsychotics in older people with dementia [6].
These figures are likely to underestimate PDRM caused
in primary care, since the negative consequences of
under-use of effective guideline recommended drugs
have not consistently been considered by the hospitalisa-
tion studies included in systematic reviews [1-4].
The ‘Data-driven Quality Improvement in Primary care
(DQIP)’ research programme is designing and testing a
complex intervention to improve the quality and safety of
medication use in UK primary care. It is based on
encouraging and facilitating primary care medical prac-
tices to systematically and continuously identify, correct or
otherwise manage drug therapy risks that are potential
pre-cursors to PDRM [7]. The DQIP approach requires
explicit medication assessment criteria which can (1) be
operationalised in existing UK electronic data sources in
order to (2) identify patients at risk of common or severe
PDRM in primary care.
A number of explicit medication assessment tools have
been developed in recent years. The Beers criteria set [8]
lists potentially inappropriate drugs in the elderly and can
be relatively easily implemented in electronic data sets.
However, a large proportion of listed items are not
licensed or rarely used in the UK and many of the drug
groups frequently associated with preventable harm are
not considered. More recently published tools that also
focus on the elderly, such as ‘Assessing care of vulnerable
elders’ (ACOVE) [9], ‘Screening Tool of Older Person’s
Prescriptions (STOPP)’ and ‘Screening Tool to Alert doc-
tors to Right Treatment’ (START) [10] have a broader
scope, but many of the included criteria require manual
record review and/or clinical judgement, which are bar-
riers to routine or large scale applications. Other instru-
ments that have been implemented in electronic records
and target the primary care population at large [11-13]
cover a limited spectrum of medication use issues, espe-
cially with respect to medication safety.
The study had two aims. First, we aimed to develop
and classify by clinical importance a set of up-to-date
medication assessment criteria that can be implemented
in routine primary care clinical datasets to identify
instances of (a) sub-optimally effective medication use
for conditions commonly encountered in primary care
and (b) high-risk use of drugs that have been shown to
either commonly cause harm and/or cause severe harm
in primary care. Second, we aimed to elicit the extent to
which thematically-related medication assessment cri-
teria, subsequently referred to as topics, are perceived to
be priorities for quality improvement by professionals
working in UK primary care.
Methods
Study design
The study was conducted in three stages. First, an exten-
sive list of candidate medication assessment criteria was
generated based on a structured literature review. Sec-
ond, an expert panel participating in a modified RAND/
UCLA (University College of Los Angeles) Appropriate-
ness Method (RAM) study scored these items by clinical
importance based on a summary of research evidence
and their clinical judgement. Candidate criteria with high
importance scores were translated into a final criteria set
by removing redundancies (see below). Final criteria were
characterised by the type of medication use targeted,
informed by available taxonomies [13-15]. Third, thema-
tically related final criteria were clustered into medication
improvement topics and those derived from candidates
with high importance scores were presented to a larger
Delphi panel of clinicians working in UK primary care
for prioritisation. The study was approved by the Tayside
Committee on Medical Research Ethics A (reference no.
09/S1401/54).
Literature review
Prescribing is a ubiquitous feature of medical care which
makes a systematic evaluation of the literature on pre-
scribing quality or safety unfeasible in a single research
project. We therefore focussed on medication use for
conditions commonly encountered in primary care and
drugs with clear evidence of significant benefit or harm.
The literature review drew initially on UK national clini-
cal guidelines, prescribing advice, and safety alerts, sup-
plemented by European or other clinical guidelines and
targeted primary literature review in selected areas as
detailed below.
Candidate medication assessment criteria either
described potentially beneficial medication use (’quality’)
or the use of potentially harmful treatments (’safety’).
Candidate ‘quality’ criteria targeted common conditions
where there are compelling indications for drug therapy
based on UK and European guidelines [16-25]. Common
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conditions that may or may not require drug treatment
for adequate management (depression, anxiety, dyspep-
sia, acute infections) or where we anticipated that
undertreated patients would not be reliably identifiable
from UK electronic data sets (chronic pain, chronic
obstructive pulmonary disease, rheumatoid arthritis,
thyroid disorders, epilepsy) were not considered. The
following conditions were selected: primary and second-
ary prevention of vascular disease [26,27], management
of diabetes [28], heart failure [29], atrial fibrillation [30],
asthma [31] and osteoporosis [32,33].
In order to identify candidate safety criteria, the drug
groups reported to be most frequently implicated in
PDRM hospital admissions were identified from systema-
tic reviews and large scale studies [1-4,34]. For each drug
or drug group identified, a more extensive literature
search was conducted in order to identify patient and/or
treatment related risk factors that make patients particu-
larly vulnerable to drug-related toxicity by virtue of age,
medical history, co-prescription, treatment duration and/
or dose. Standard medicines information resources
[35-39] and the primary research literature were consid-
ered in addition to selected previously published medica-
tion assessment instruments [8-10,40]. Safety alerts in
the British National Formulary [36], the UK National
Prescribing Centre [38] and the Medicines and Health-
care products Regulatory Agency [39] were examined to
identify prescribing that was less commonly reported to
be implicated in drug-related hospital admissions but
associated with severe harm. Candidate safety criteria tar-
geting potentially harmful prescribing in vulnerable
groups were identified drawing on the above literature
sources (children and young adults, the elderly) as well as
current clinical practice guidelines (heart failure [22]).
Potentially important aspects of high-risk prescribing
that relied on data items which are not consistently
recorded in UK primary care electronic data sets (moni-
toring or achievement of international normalised ratio
targets, monitoring of blood glucose in patients co-pre-
scribed drugs known to enhance sensitivity to insulin or
oral anti-diabetics, medication use in pregnancy/lacta-
tion) were excluded.
RAND/UCLA Appropriateness Method (RAM) study
The RAND/University of California Los Angeles
(UCLA) appropriateness method is a rigorous way of
combining research evidence with expert opinion [41],
and has previously been applied to develop explicit cri-
teria for the assessment of a range of health care proce-
dures including medication use [42]. A panel of ten
members was selected with clinical, public health or
academic expertise in medication use in UK primary
care. The panel was composed of four general medical
practitioners (of whom two had National Health Service
prescribing improvement roles) and six pharmacists
(including two academics with a special interest in pri-
mary care, two working in medicines governance at
health board level, and two working directly with gen-
eral practices). All ten participants completed two
rounds of scoring.
The questionnaire aimed to classify candidate medica-
tion assessment criteria derived from the literature as
either ‘necessary’ or ‘appropriate’ care (table 1). ‘Neces-
sary’ is a more stringent rating standard than ‘appropri-
ate’, because it represents care that would be ‘improper’
not to be offered or avoided, whereas ‘appropriate’ is a
more neutral balancing of net benefit or harm [43-45].
Following the RAM recommendations, ordinal scales of
1 to 9 were used for all ratings [43,46].
All candidate quality and safety assessment criteria
were scored for ‘appropriateness’. Candidate criteria
with a median rating of 4 to 6 (’uncertain’) or disagree-
ment (three or more ratings of 7 to 9 and three or
more ratings of 1 to 3) on the appropriateness scale
were rejected. Those items with median ratings of 7 to
9 were accepted as ‘appropriate’ and those with median
ratings of 1 to 3 as ‘inappropriate’.
Candidate quality assessment criteria were additionally
scored on a ‘necessary to do’ scale, where items with a
median rating of 7 to 9 (= clearly necessary to do) were
accepted. Candidate safety assessment criteria were
additionally scored on a ‘necessary to avoid’ scale, where
items with a median rating of 1 to 3 (= clearly necessary
to avoid) were accepted. Candidate criteria with median
ratings of < 7 on the ‘necessary to do’ and > 3 on the
necessary to avoid scale and those showing disagree-
ment (defined as above) were rejected. The concept of
‘necessary to avoid’ was an extension to the original
RAM method to differentiate between prescribing that
is ‘generally not worthwhile’ from ‘improper’ in safety
terms (see box 2).
The ten RAM panel members were emailed the first
round questionnaire and a summary of the supporting
evidence base. Panellists were asked to rate each item
with reference to an ‘average’ patient consulting an
‘average’ primary care clinician in 2009 based on both
the evidence summary and their clinical judgement [44].
Panellists subsequently met for a full day, where a sum-
mary of the first round ratings was fed back to panellists
anonymously. This formed the basis for a moderated
discussion of each item before the second round ratings
were placed. All findings reported in this paper are
based on second round ratings.
Delphi study
A random sample of general medical practitioners (GPs)
and eligible pharmacists in Scotland and England was
invited to participate by e-mail. In order to be eligible,
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pharmacists had to have experience of working in medi-
cines governance, as a prescribing advisor or as a prac-
tice pharmacist. Twenty three (64%) GPs and 13 (36%)
pharmacists agreed to participate.
The Delphi questionnaire listed the medication
improvement topics to be scored together with a short
summary of the scientific rationale for each topic. For
each item, panellists were asked to state their level of
agreement with the statement ’The described topic is a
priority for collaborative quality improvement in primary
care’. The term ‘collaborative’ was used in order to
emphasise that the intended purpose of this study was
to identify priority topics for quality improvement rather
than measures for judging practitioners or practices as
part of performance management.
As in the RAM study, all ratings used an ordinal scale of
1 to 9 (1 = strongly disagree and 9 = strongly agree).
Panellists were instructed to rate topics in relation to pri-
mary care in general, rather than their own practice. The
first round ratings were summarised and returned to parti-
cipants by email for a second round of scoring. Topics
with second round median ratings of 7 to 9 without dis-
agreement (30% or more ratings of 1 to 3 and 30% or
more ratings of 7 to 9) were accepted as ‘priority’, with
median ratings of 8 or 9 defined as ‘high priority’. All find-
ings reported in this paper refer to second round ratings.
Results
Literature review and RAM study
The questionnaire listed 389 (100 quality and 289 safety)
candidate assessment criteria. Upon completion of the
second rating round, 318 (82%) candidates (93 quality
and 225 safety) were accepted at the ‘appropriate’ and
275 (71%) items (73 quality and 202 safety) at the
‘necessary’ level. A number of candidate criteria were
duplicates, in the sense that they were designed to
determine thresholds beyond which care was judged
appropriate and necessary. For example, 18 candidate
quality assessment criteria related to glycated haemoglo-
bin (HbA1c) levels beyond which treatment intensifica-
tion was appropriate or necessary. Removing redundant
candidate criteria yielded 52 quality and 124 safety
assessment criteria to be included in the final set. Forty
(77%) final quality assessment criteria and 107 (86%)
final safety assessment criteria were derived from candi-
dates accepted at the ‘necessary’ level. The results of the
RAM study are summarised in tables 2 and 3 and the
final list of quality and safety assessment criteria is pre-
sented in tables 4 and 5.
Table 2 shows the number of accepted quality assess-
ment criteria categorised (1) by medical condition and
(2) by four medication quality categories (MQ 1 to 4)
referring to ‘need (indication)’, ‘selection’ or ‘intensity’ of
drug treatment that were informed by available taxo-
nomies [13-15]. The majority (87%) of the final 52 qual-
ity assessment criteria focus on the prevention
(including diabetes mellitus) or management of vascular
disease with lower proportions addressing asthma (8%)
and osteoporosis (6%). Over half (52%) of final quality
criteria target patients with unmet indications for drug
therapy (MQ1) and 43% focus on treatment intensity
(MQ3 and MQ4) for effective disease management with
the remainder (8%) targeting selection of first line agents
within a therapeutic class (MQ2).
Similarly, table 3 categorises the number of accepted
safety assessment criteria generated (1) by high-risk
drug or patient group targeted and (2) by eight medica-
tion safety categories (MS 1 to 8), referring to ‘need
(indication)’, ‘selection’, treatment ‘intensity’, ‘compli-
ance’ issues and ‘monitoring’.
The majority of safety assessment criteria are drug-
focussed (74%), either targeting drugs reported to be fre-
quently implicated in PDRM hospital admissions (54% -
section A) or others implicated in severe preventable
harm (20% - section B). The remainder (26% - section
C) target medication use in particularly vulnerable
groups, namely the elderly (15%), patients with heart
failure (8%) and children (4%). Over a third (36%) of
final safety assessment criteria focus on potentially
harmful use of NSAIDs, antiplatelets, anticoagulants and
diuretics, the drug groups most frequently implicated in
PDRM hospital admissions [1].
Table 1 Definitions of rating categories used in the modified RAM study [55]
Rating category Definition
’Appropriate’ In an average patient, the expected health benefit usually exceeds the expected negative consequences by a sufficiently wide
margin that prescribing is worthwhile, irrespective of cost
’Inappropriate’ In an average patient, the expected negative consequences usually exceed the expected health benefits by a sufficiently wide
margin that prescribing is not worthwhile, irrespective of cost
’Necessary to do’ In an average patient, it would be considered improper care NOT to prescribe as stated, because
(1) there is sufficient evidence, that the patient is likely to benefit AND
(2) the likely benefit to the patient is large enough to be clinically significant
’Necessary to
avoid’
In an average patient, it would be considered improper care to prescribe as stated, because
(1) there is sufficient evidence, that the patient is likely to be harmed AND
(2) the likely harm to the patient is large enough to be clinically significant
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Over half (52%) of safety criteria target the selection of
high-risk drugs (MS2 to 4), either for indications where
safer (and equally effective) alternatives exist (MS2) or in
patients particularly susceptible to adverse reactions
because of age/co-morbidity (MS3) or co-prescription
(MS4). A further 15 (12%) criteria target omissions of
drugs indicated to mitigate the risk of adverse events from
high-risk treatments (MS1), while twenty (16%) criteria tar-
get inconsistent laboratory monitoring (MS8). Two (2%)
criteria focus on prescribing that may jeopardise patient
compliance with methotrexate dosing schedules (MS7).
The majority of quality (81%) and safety (71%) assess-
ment criteria are not restricted to the elderly (patients
aged 65 years or older).
Delphi study
Grouping of thematically related assessment criteria that
were derived from candidates accepted at the ‘necessary’
level yielded a total of 47 (18 quality and 29 safety) medi-
cation improvement topics to be rated by the Delphi
panel. Thirty-six Delphi study participants completed a
first round and 26 (73%) a second round questionnaire
(table 6). Fifteen (83%) quality and 23 (79%) safety topics
were accepted as ‘priorities for quality improvement in
primary care’. Eleven (7 quality and 4 safety) topics were
classified as ‘high priorities’ and nine (3 quality and 6
safety) topics were rejected because of lower than stipu-
lated median ratings (table 7). There were no differences
between pharmacists and GPs with respect to the
Table 2 Summary of final quality assessment criteria designed from candidates accepted in the modified RAM study
as appropriate (App) or necessary to do (NecDo)
Condition targeted Final quality assessment criteria
Medication quality category (MQ):
Targeted prescribing
Associated PDRM event Count
App NecDo Total
HYPERTENSION MQ2: Selection of first line antihypertensives CV events - 1 13 (25%)
MQ3: Blood pressure control CV events 5 7
DIABETES MQ1: Use of ACEI/ARB if micro-albuminuria DM complications - 1 6 (12%)
MQ2: Selection of metformin if overweight DM complications - 1
MQ3: HbA1c control DM complications 2 2
AT RISK OF PRIMARY/SECONDARY
VASCULAR EVENTS
MQ1: Use of antiplatelet or anticoagulant CV events 1 4 17 (33%)
Use of statin CV events 1 3
Use of ACEI or ARB in CHD CV events 1 1
Use of beta blockers in CHD CV events - 2
MQ4: Achievement of target statin dose CV events - 4
CHRONIC HEART
FAILURE
MQ1: Use of ACEI or ARB CHF progression - 1 5(10%)
Use of beta blocker CHF progression - 1
MQ2: Selection of beta blocker licensed for CHF CHF progression 1 -
MQ4: Achievement of target ACEI/ARB dose CHF progression - 1
Achievement of target BB dose CHF progression - 1
ATRIAL FIBRILLATION MQ1: Use of antiplatelet or anticoagulant Stroke/Embolism - 3 4(8%)
MQ2: Selection of warfarin in high risk of stroke Stroke/Embolism - 1
ASTHMA MQ1: Use of inhaled corticosteroid Asthma exacerbation 1 3 4 (8%)
OSTEOPOROSIS MQ1: Use of bone protecting agent Fractures - 1 3(6%)
Use of calcium/vitamin D supplement Fractures - 2
Total 12 40 52 (100%)
Medication Quality categories
1. INDICATION MQ1: Need for treatment to control condition 4 22 26 (52%)
2. SELECTION MQ2: Selection of first line option within drug class 1 3 4 (8%)
3. INTENSITY MQ3: Achievement of intermediate outcome target 7 9 16 (31%)
MQ4: Achievement of target dose - 6 6 (12%)
Criteria restricted to the elderly
Aged ≥ 75 4 4 8 (15%)
Aged ≥ 80 - 2 2 (4%)
MQ1 to 4 refer to medication quality categories as specified in the bottom half of the table.
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Table 3 Summary of final safety assessment criteria designed from candidates accepted in the modified RAM study as
inappropriate (InApp) or necessary to avoid (NecAv)
High-risk drug/patient group Final safety assessment criteria
Medication safety category (MS):
Targeted prescribing/monitoring
Associated PDRM event Count
InApp NecAv Total
Drugs frequently implicated in PDRM hospital admissions
ANTIPLATELET MS1: Use without gastroprotection GI toxicity/bleeding 1 4 5 (4%)
DIURETIC MS1: Unmet need for allopurinol in thiazide users Gout - 1 11 (9%)
MS3: Use of thiazides in CKD Renal toxicity - 1
Use of aldosterone antagonist in CKD Hyperkalaemia - 1
MS6: Excess duration of potassium supplement Hyperkalaemia - 1
MS8: Inconsistent monitoring of U&E’s Electrolyte disturbances 2 5
NSAID MS1: Unmet need for gastroprotection GI toxicity/bleeding 1 4 18 (15%)
MS2: Use of COX II selective agents in aspirin users CV events - 1
Paracetamol not tried first General NSAID toxicity 1 2
MS3: Use in CKD Renal toxicity - 2
Use of COX II selective agents in high CV risk CV events - 2
MS4: Co-prescription with diuretic and/or ACEI or ARB Renal toxicity 2 3
ANTICOAGULANT MS2: Use of warfarin in AF and low risk of stroke Bleeding - 1 11 (9%)
MS4: Co-prescription of high-risk anti-infectives Bleeding 1 9
OPIOID MS1: No laxative co-prescribed in strong opioid users Constipation 1 1 2 (2%
BETA BLOCKER MS3: Use in asthma Asthma exacerbation 1 2 4 (3%)
MS4: Co-prescription with verapamil/diltiazem Bradycardia - 1
ACEI/ARB MS8: Inconsistent monitoring of U&E’s Hyperkalaemia - 2 2 (2%)
ANTIDIABETIC MS3: Use of long acting sulphonylureas in CKD Hypoglycaemia - 1 2 (2%)
Use of metformin in CKD Lactic acidosis - 1
DIGOXIN MS5: Excessive dose in CKD or the elderly Digoxin toxicity - 2 10 (8%)
Excessive dose in patients on interacting drugs - 6
MS8: Inconsistent monitoring of U&E’s - 2
ORAL STEROID MS1: Unmet need for bone protecting agents Bone fracture - 2 2 (2%)
Other drugs implicated in severe adverse drug events
DMARD MS7: Lack of dose instructions/Use of 2 strengths Miscellaneous - 2 10 (8%)
MS8: Inconsistent monitoring of FBC Blood dyscrasias 2 6
FEMALE MS3: Use of estrogens in women w/o hysterectomy Gynaecological cancer - 1 7 (6%)
STEROIDS MS3: Use in women with CVD or CVD risk > 20% Vascular events 2 2
MS6: Excess duration in postmenopausal women 1 1
AMIODARONE MS8: Inconsistent monitoring of thyroid function Thyroid disturbances - 1 1 (1%)
THEOPHYLLIN MS2: Use without inhaled anticholinergics/steroids Theophylline toxicity - 1 1 (1%)
STATIN MS5: Excessive dose in patients on interacting drugs Rhabdomyolysis - 5 5 (4%)
Particularly vulnerable patient groups
ELDERLY MS3: Miscellaneous drugs to be avoided Miscellaneous 1 10 18 (15%)
MS6: Miscellaneous drugs for excessive duration Miscellaneous - 7
HEART FAILURE MS3: Miscellaneous drugs to be generally avoided HF exacerbation - 10 10 (8%)
CHILDREN MS3: Miscellaneous drugs to be generally avoided Miscellaneous 1 4 5 (4%)
Total 17 107 124 (100%)
Medication Safety (MS) categories
1. INDICATION MS1: Unmet need for risk mitigating drug 3 12 15 (12%)
2. SELECTION MS2: High risk drug without compelling indication 1 5 64 (52%)
MS3: Drug-disease or Drug-age interaction 5 37
MS4: Drug-Drug interaction (DDI) 3 13
3. INTENSITY MS5: Excessive dose - 13 23 (19%)
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Table 3 Summary of final safety assessment criteria designed from candidates accepted in the modified RAM study as
inappropriate (InApp) or necessary to avoid (NecAv) (Continued)
MS6: Excessive duration 1 9
4. COMPLIANCE MS7: Issues related to patient compliance - 2 2 (2%)
5. MONITORING MS8: Inconsistent laboratory monitoring 4 16 20 (16%)
Criteria restricted to the elderly
Aged ≥ 65 3 21 24 (19%)
Aged ≥ 75 2 9 11 (9%)
Aged ≥ 85 1 - 1 (1%)
MS 1 to 8 refer to medication quality categories as specified in the bottom half of the table.
Table 4 Quality assessment criteria generated from candidates that the RAM panel classified as ‘appropriate but not
necessary to do’ (A) and ‘appropriate and necessary to do’ (N)
Topic No. Treatment targeted - Associated PDRM event (Medication quality category)
HYPERTENSION
Q1 Selection of first line antihypertensives - Hypertension complications (MQ2)
1. (N) Patient with HTN and without CHD - is started on antihypertensive treatment with a first-line antihypertensive
Q2 Treatment to blood pressure (BP) target - Hypertension complications (MQ3)
Patient aged < 75 years, who has a history of hypertension WITHOUT complications
2. (N) and BP is > 150/90 mmHg on < 3 antihypertensive drugs - has antihypertensive treatment intensified
3. (N) and BP is > 140/85 mmHg on < 2 antihypertensive drugs - has antihypertensive treatment intensified
4. (A) and BP is > 140/85 mmHg on < 3 antihypertensive drugs - has antihypertensive treatment intensified
Patient aged ≥ 75 years, who has a history of hypertension WITHOUT complications
5. (N) and BP is > 150/90 mmHg on < 2 antihypertensive drugs - has antihypertensive treatment intensified
6. (N) and BP is > 140/85 mmHg without antihypertensive treatment - has antihypertensive treatment started
7. (A) and BP is > 150/90 mmHg on < 3 antihypertensive drugs - has antihypertensive treatment intensified
8. (A) and BP is > 140/85 mmHg on < 2 antihypertensive drugs - has antihypertensive treatment intensified
Patient aged < 75 years, who has a history of hypertension WITH complications
9. (N) and BP is > 130/80 mmHg on < 2 antihypertensive drugs - has antihypertensive treatment intensified
Patient aged ≥ 75 years, who has a history of hypertension WITH complications
10. (N) and BP is > 140/85 mmHg on < 2 antihypertensive drugs - has antihypertensive treatment intensified
11. (N) and BP is > 130/80 mmHg without antihypertensive treatment - has antihypertensive treatment intensified
12. (A) and BP is > 140/85 mmHg on < 3 antihypertensive drugs - has antihypertensive treatment intensified
13. (A) and BP is > 130/80 mmHg on < 2 antihypertensive drugs - has antihypertensive treatment intensified
DIABETES MELLITUS
Q3 Treatment to HbA1c target - Diabetes complications (MQ3)
Patient with diabetes mellitus type 2,
14. (N) who has HbA1c of > 7% on < 2 oral antidiabetic drugs - has antidiabetic treatment intensified
15. (N) who has HbA1c of > 9% on < 3 oral antidiabetic drugs - has antidiabetic treatment intensified
16. (A) who has HbA1c of 6.6 to 7% without antidiabetic treatment - has antidiabetic treatment intensified
17. (A) who has HbA1c of 7.6 to 9% on < 3 oral antidiabetic drugs - has antidiabetic treatment intensified
Q4 Selection of first line oral antidiabetic - Diabetes complications (MQ2)
18. (N) Patient with diabetes mellitus type 2, who is overweight - is started on metformin
Q5 Indication for ACEI or ARB in patients with renal complications - Diabetes complications (MQ1)
19. (N) Patient with diabetes mellitus and micro-albuminuria - is prescribed an ACEI or ARB
AT RISK OF/MANIFEST VASCULAR DISEASE
Q6 Indication for statin in patients with manifest vascular disease or risk factors - Vascular events (MQ1)
20. (N) Patient with previous vascular events (MI, stroke or TIA) - is prescribed a statin
21. (N) Patient with peripheral vascular disease - is prescribed a statin
22. (N) Patient aged > 40 with DM without established vascular disease - is prescribed a statin
23. (A) Patient with 10 year CVD risk > 20% without diabetes - is prescribed a statin
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Table 4 Quality assessment criteria generated from candidates that the RAM panel classified as ‘appropriate but not
necessary to do’ (A) and ‘appropriate and necessary to do’ (N) (Continued)
Q7 Treatment to target statin dose in patients with manifest vascular disease or risk factors - Vascular events (MQ4)
24. (N) Patient with previous vascular events (MI, stroke or TIA) - is prescribed simvastatin ≥ 40 mg/d (or equivalent)
25. (N) Patient with peripheral vascular disease - is prescribed simvastatin ≥ 40 mg/d (or equivalent)
26. (N) Patient aged > 40 with DM without established vascular disease - is prescribed simvastatin ≥ 40 mg/d (or equiv.)
27. (N) Patient with 10 year CVD risk > 20% without diabetes - is prescribed simvastatin ≥ 40 mg/d (or equivalent)
Q8 Indication for thrombo-embolic prophylaxis in patients with CHD - Vascular events (MQ1)
28. (N) Patient with previous vascular events (MI, stroke or TIA) - is prescribed any thrombo-embolic prophylaxis
29. (N) Patient with a history of peripheral vascular disease - is prescribed any thrombo-embolic prophylaxis
Indication for dual antiplatelets in CHD with a history of ACS - Vascular events (MQ1)
30. (N) Patient with previous stroke/TIA - is co-prescribed aspirin and dipyridamole (unless on warfarin or clopidogrel)
31. (N) Patient with ACS 0 to 3 months ago - is co-prescribed aspirin and clopidogrel (unless on warfarin)
32. (A) Patient with ACS 4 to 9 months ago - is co-prescribed aspirin and clopidogrel (unless on warfarin)
Q9 Indication for beta blockers in CHD - Vascular events (MQ1)
33. (N) Patient with a history of acute coronary syndrome - is prescribed a beta blocker
34. (N) Patient with stable angina without a history of acute coronary syndrome - is prescribed a beta blocker
Q10 Indication for ACEI or ARB in CHD - Vascular events (MQ1)
35. (N) Patient with a history of acute coronary syndrome - is prescribed an ACEI or ARB
36. (A) Patient with stable angina without a history of acute coronary syndrome - is prescribed an ACEI or ARB
CHRONIC HEART FAILURE
Q11 Indication for ACEI or ARB in CHF - Heart failure progression (MQ1)
37. (N) Patient with CHF - is prescribed an ACE or ARB
Q12 Indication for Beta blocker in CHF - Heart failure progression (MQ1)
38. (N) Patient with CHF - is prescribed a beta blocker
Selection of licensed beta blocker in CHF - Heart failure progression (MQ2)
39. (A) Patient with CHF and treated with a BB - is prescribed a BB licensed for CHF
Q13 Treatment to target dose (ACEI and ARB) in CHF - Heart failure progression (MQ4)
40. (N) Patient with CHF and treated with an ACEI or ARB - has achieved the recommended target dose
Q13 Treatment to target dose (beta blocker) - CHF- Prevention of heart failure progression (MQ4)
41. (N) Patient with CHF and treated with a beta blocker - has achieved the recommended target dose
ATRIAL FIBRILLATION
Q14 Indication for thrombo-embolic prophylaxis in AF - Thrombo-embolism (MQ1)
42. (N) Patient with atrial fibrillation and a CHADS2 score of 0 or 1 - is prescribed thrombo-embolic prophylaxis
43. (N) Patient with atrial fibrillation and a CHADS2 score of 2 - is prescribed thrombo-embolic prophylaxis
44. (N) Patient with atrial fibrillation and a CHADS2 score ≥ 3 - is prescribed thrombo-embolic prophylaxis
Q15 Selection of thrombo-embolic prophylaxis in AF - Thrombo-embolism (MQ2)
45. (N) Patient with AF and a CHADS2 score ≥ 3 treated with an antithrombotic - is prescribed an oral anticoagulant
ASTHMA
Q16 Indication for inhaled corticosteroids in asthma - Asthma exacerbation (MQ1)
Patient aged > 4 with asthma but without COPD and
46. (N) is treated with a step 3 drug* - is also prescribed an inhaled corticosteroid
47. (N) has received oral prednisolone in last 12 weeks - is also prescribed an inhaled corticosteroid
48. (N) has received ≥ 3 prescriptions of SABAs in last 12 weeks - is also prescribed an inhaled corticosteroid
49. (A) has received 2 prescriptions of SABAs in last 12 weeks - is also prescribed an inhaled corticosteroid
* long acting beta agonist, leukotriene receptor antagonist or theophylline
OSTEOPOROSIS
Q17 Indication for bone protecting agents in patients with osteoporosis - Fractures (MQ1)
50. (N) Female patient with osteoporosis who had a vertebral fracture - is prescribed a bone protecting agent*
* a bisphosphonate, strontium ranelate, raloxifene or teriparatide
Q18 Indication for Calcium/vitamin D in patients at risk of osteoporosis - Fractures (MQ1)
51. (N) Female patient aged ≥ 80 who is housebound - is prescribed calcium and vitamin D
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Table 4 Quality assessment criteria generated from candidates that the RAM panel classified as ‘appropriate but not
necessary to do’ (A) and ‘appropriate and necessary to do’ (N) (Continued)
52. (N) Female patient aged ≥ 80 who lives in a nursing home/residential care - is prescribed calcium and vitamin D
The criteria are organised hierarchically by medical condition, followed by the drug group targeted, quality topic scored in the Delphi study (Q) and by
medication use quality category (MQ). MQ1 = indication for beneficial treatment, MQ2 = Selection of most effective option within drug class, MQ3 =
Achievement of intermediate outcome target, MQ4 = Achievement of target dose
Table 5 Safety assessment criteria generated from candidates that the RAM panel classified as ‘inappropriate’ (I) or
‘necessary to avoid’ (N)
Topic No. Treatment targeted - Associated PDRM event (Medication safety category)
A. DRUGS FREQUENTLY IMPLICATED IN PDRM HOSPITAL ADMISSIONS
ANTIPLATELETS
S1 High-risk use without gastro-intestinal protection (GIP) - GI toxicity/bleeding (MS1)
1. (N) Patient with previous peptic ulcer (PU) treated with low dose aspirin - is not prescribed GIP
2. (N) Patient aged ≥ 65 treated with warfarin AND low dose aspirin - is not prescribed GIP
3. (N) Patient aged ≥ 65 treated with warfarin AND clopidogrel - is not prescribed GIP
4. (N) Patient aged ≥ 65 treated with low dose aspirin AND clopidogrel - is not prescribed GIP
5. (I) Patient aged ≥ 75 years treated with low dose aspirin - is not prescribed GIP
NSAIDS
S1 High-risk use without gastroprotection (GIP) - GI toxicity/bleeding (MS1)
6. (N) Patient with previous PU treated with an oral NS NSAID for > 12 weeks - is not prescribed GIP
7. (N) Patient is aged ≥ 75 years treated with an oral NS NSAID for > 12 weeks - is not prescribed GIP
8. (I) Patient is aged 65 to 74 treated with an oral NS NSAID for > 12 weeks - is not prescribed GIP
S1 High-risk use without gastroprotection - GI toxicity/bleeding (MS1)
9. (N) Patient aged ≥ 65 treated with warfarin AND an oral NS NSAID - is not prescribed GIP
10. (N) Patient aged ≥ 65 treated with low dose aspirin AND an oral NS NSAID for > 12 weeks - is not prescribed GIP
S2 High risk drug without compelling indication - General drug specific toxicity (MS2)
11. (N) Patient aged ≥ 65 - is prescribed an oral NSAID for osteoarthritis without previous trial of full dose paracetamol
12. (N) Patient aged ≥ 75 - is prescribed an oral NSAID for minor trauma without previous trial of full dose paracetamol
13. (I) Patient aged 65 to 74 - is prescribed an oral NSAID for minor trauma without previous trial of full dose paracetamol
S3 High-risk selection in renal impairment - Renal toxicity (MS3)
14. (N) Patient with CKD stage 3 - is prescribed an oral NSAID
15. (N) Patient with CKD stage 4 or 5 - is prescribed an oral NSAID
S3 Drug-Drug interaction (additive toxicity) - Renal toxicity (MS4)
16. (N) Patient aged ≥ 65 treated with an ACEI or ARB but no diuretic - is co-prescribed an oral NSAID
17. (N) Patient aged ≥ 75 treated with a diuretic but no ACEI or ARB - is co-prescribed an oral NSAID
18. (N) Patient treated with an ACEI or ARB AND a diuretic - is co-prescribed an oral NSAID
19. (I) Patient aged ≤ 65 treated with an ACEI or ARB but no diuretic - is co-prescribed an oral NSAID
20. (I) Patient aged 65 to 74 treated with a diuretic but no ACEI or ARB - is co-prescribed an oral NSAID
S4 High-risk drug without compelling indication - CV events (MS2)
21. (N) Patient treated with low-dose aspirin - is prescribed an oral COX II selective NSAID
S5 High-risk selection in patients at high vascular risk- Vascular events (MS3)
22. (N) Patient aged > 40 and CVD risk > 20% - is prescribed a COX II selective NSAID
23. (N) Patient with a history of vascular events - is prescribed a COX II selective NSAID
DIURETICS
S6 Monitoring of U&E’s - Electrolyte imbalance (MS8)
24. (N) Patient treated with a potassium sparing diuretic -had no U&Es check before treatment start
25. (N) Patient treated with a potassium sparing diuretic - had no U&Es check in the last 48 weeks
26. (N) Patient treated with a loop diuretic - had no U&Es check before treatment start
27. (N) Patient treated with a loop AND a thiazide diuretic or metolazone - had no U&Es check in the last 24 weeks
28. (N) Patient treated with a potassium sparing diuretic AND an ACEI or ARB - had no U&Es check in the last 48 weeks
29. (I) Patient treated with a potassium wasting diuretic - had no U&Es check in the last 48 weeks
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Table 5 Safety assessment criteria generated from candidates that the RAM panel classified as ‘inappropriate’ (I) or
‘necessary to avoid’ (N) (Continued)
30. (I) Patient treated with a potassium sparing diuretic AND an ACEI or ARB - had no U&Es check in the last 24 weeks
S7 High-risk selection in renal impairment - Renal toxicity/Treatment failure (MS3)
31. (N) Patient with chronic kidney disease stage 4 or 5 - is prescribed a thiazide diuretic
S8 High-risk use without allopurinol - Gout (MS1)
32. (N) Patient with a history of gout and treated with a thiazide diuretic - is not prescribed allopurinol
S9 High-risk selection in renal impairment - Electrolyte imbalance (MS3)
33. (N) Patient with CKD stage 4 or 5 - is prescribed an aldosterone antagonist
S10 Excess duration - Electrolyte imbalance (MS6)
34. (N) Patient treated with a potassium (KI) sparing diuretic - is prescribed a K+ supplement for ≥ 4 weeks
ANTICOAGULANTS
S11 Drug-Drug interaction (pharmacokinetic) - Bleeding (MS4)
35. (N) Patient treated with warfarin - is co-presribed a macrolide
36. (N) Patient treated with warfarin - is co-prescribed a sulfonamide
37. (N) Patient treated with warfarin - is co-prescribed an azole antifungal
38. (N) Patient treated with warfarin - is co-prescribed metronidazole
39. (N) Patient treated with warfarin - is co-prescribed chloramphenicol
40. (N) Patient treated with warfarin- is co-prescribed isoniazid
41. (N) Patient treated with warfarin - is co-prescribed rifampin
42. (N) Patient treated with warfarin - is co-prescribed griseofulvin
43. (N) Patient treated with warfarin - is co-prescribed ribavirin
44. (I) Patient treated with warfarin - is co-prescribed tetracyclines
S12 High risk drug without compelling indication- Bleeding (MS2)
45. (N) Patient with atrial fibrillation - is prescribed warfarin despite CHADS2 score = 0
OPIOIDS - CONSTIPATION
S13 High-risk use without laxative - Constipation (MS1)
46. (N) Patient treated with a strong opioid (morphine > 10 mg or equivalent) for > 4 weeks - is not prescribed a laxative
47. (I) Patient aged ≥ 65 treated with a strong opioid (morphine > 10 mg or equivalent) - is not prescribed a laxative
BETA BLOCKERS
S14 Drug-drug interaction (additive toxicity) - Bradycardia (MS4)
48. (N) Patient treated with a beta-blocker - is co-prescribed verapamil or diltiazem
S15 High-risk selection in asthma - Asthma exacerbation (MS3)
49. (N) Patient with active asthma (prescribed beta agonist inhaler in last year) without COPD - is prescribed any oral BB
50. (N) Patient with active asthma without COPD - is prescribed a non-cardio-selective oral BB
51. (I) Patient with active asthma without COPD - is prescribed beta-blocker eye drops
ACE INHIBITORS (ACEIs) AND ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)
S6 Monitoring of U&E’s - Electrolyte imbalance (MS8)
52. (N) Patient co-prescribed an ACEI AND ARB - has not had a U&Es check > 24 weeks ago
Monitoring of U&E’s - Electrolyte imbalance (MS8)
53. (N) Patient prescribed an ACEI or ARB - has not had a U&Es check before treatment start
ANTIDIABETICS
S16 High-risk selection in renal impairment- Lactic acidosis (MS3)
54. (N) Patient with chronic kidney disease (CKD) stage 4 or 5 - is prescribed metformin
S17 High-risk selection in renal impairment - Hypoglycaemia (MS3)
55. (N) Patient with CKD stage 4 or 5 - is prescribed a sulphonylurea other than gliclazide or tolbutamide
DIGOXIN
S18 Excessive dose (Elderly) - General digoxin toxicity (MS5)
56. (N) Patient aged ≥ 65 years - is prescribed digoxin ≥ 250 mcg/day
57. (N) Patient with CKD stage 3, 4 or 5 (eGFR < 60) - is prescribed digoxin ≥ 250 mcg/day
S18 Excessive dose (DDI without dose adjustment) - General digoxin toxicity (MS5)
58. (N) Patient treated with digoxin and amiodarone - is prescribed digoxin ≥ 250 mcg/day
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Table 5 Safety assessment criteria generated from candidates that the RAM panel classified as ‘inappropriate’ (I) or
‘necessary to avoid’ (N) (Continued)
59. (N) Patient treated with digoxin and propafenone - is prescribed digoxin ≥ 250 mcg/day
60. (N) Patient treated with digoxin and chloroquine or hydroxychloroquine - is prescribed digoxin ≥ 250 mcg/day
61. (N) Patient treated with digoxin and quinine - is prescribed digoxin ≥ 250 mcg/day
62. (N) Patient treated with digoxin and a calcium channel blocker * - is prescribed digoxin ≥ 250 mcg/day
63. (N) Patient treated with digoxin and ciclosporin - is prescribed digoxin ≥ 250 mcg/day
* lercanidipine, nicardipine, nifedipine, diltiazem, verapamil)
S8 Monitoring of U&E’s - General digoxin toxicity (MS8)
64. (N) Patient is co-prescribed a potassium wasting diuretic AND digoxin with last U&Es check before treatment start
65. (N) Patient is co-prescribed a potassium wasting diuretic AND digoxin with last U&Es check > 48 weeks ago
CORTICOSTEROIDS
S19 High-risk use without bone protecting agent - Bone fracture (MS1)
66. (N) Patient aged ≥ 65 years treated with an oral corticosteroid for ≥ 12 weeks - is not prescribed bone protection *
67. (N) Patient with low trauma fracture and treated with an oral corticosteroid for ≥ 12 weeks - is not prescribed bone protection*
*a bisphosphonate, calcitriol or hormone replacement therapy
B. OTHER HIGH RISK DRUGS
DMARDS
S20 High-risk drug without taking action to ensure patient compliance - General toxicity (MS7)
68. (N) Patient treated with methotrexate - has not been given explicit dose instructions of weekly dosing
69. (N) Patient treated with methotrexate - is prescribed > 1 strength of methotrexate tablets
S21 Monitoring of full blood count (FBC) - Blood dyscrasias (MS8)
70. (N) Patient treated with auranofin - had no FBC check in the last 8 weeks
71. (N) Patient treated with aurothiomalate - had no FBC check in the last 8 weeks
72. (N) Patient treated with penicillamine - had no FBC check in the last 8 weeks
73. (N) Patient treated with leflunomide - had no FBC check in the last 12 weeks
74. (N) Patient treated with methotrexate - had no FBC check in the last 12 weeks
75. (N) Patient treated with azathioprine - had no FBC check in the last 12 weeks
76. (I) Patient treated with cyclophosphamide - had no FBC check in the last 24 weeks
77. (I) Patient treated with sulfasalazine - had no FBC check in the last 24 weeks
FEMALE HORMONES
S22 Selection in patients at high vascular risk - Vascular events (MS3)
78. (N) Patient with previous vascular disease/events - is prescribed any hormone replacement therapy (HRT)
79. (N) Patient with an estimated 10 year CVD risk ≥ 20% - is prescribed combined contraceptives
80. (I) Patient with an estimated 10 year CVD risk ≥ 20% and aged 50 to 59 - is prescribed combined HRT
81. (I) Patient with an estimated 10 year CVD risk ≥ 20% and aged ≥ 60 - is prescribed (any) HRT
S23 Excess duration - Gynaecological cancer (MS6)
82. (N) Patient aged ≥ 50 - is prescribed combined HRT for ≥ 5 years
83. (N) Patient aged ≥ 50 without hysterectomy - is prescribed estrogens without cyclical progestogen
84. (I) Patient aged ≥ 50 - is prescribed estrogens only HRT for ≥ 5 years
AMIODARONE
S24 Monitoring of thyroid function - Hypo-/Hyperthyroidism (MS8)
85. (N) Patient prescribed amiodarone - had no thyroid function test in last 9 months
THEOPHYLLINE
S25 High-risk drug without compelling indication - General theophylline toxicity (MS2)
86. (N) Patient aged ≥ 65 with COPD - is prescribed theophylline without use of a long acting beta2 - agonist or antimuscarinic
STATINS
S26 Excessive dose (DDI without dose adjustment) - Rhabdomyolysis (MS5)
87. (N) Patient treated with simvastatin and an HIV protease inhibitor - is prescribed simvastatin > 10 mg/day
88. (N) Patient treated with simvastatin and ciclosporin - is prescribed simvastatin > 10 mg/day
89. (N) Patient treated with simvastatin and verapamil - is prescribed simvastatin > 10 mg/day
90. (N) Patient treated with simvastatin and a fibrate (except fenofibrate) - is prescribed simvastatin > 10 mg/day
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assignment of priority levels, and no panel disagreement
on any topic (defined in terms of variation in scoring as
detailed in the methods section above).
Discussion
This paper reports the development of a set of 176
explicit assessment criteria to identify patients at risk of
Table 5 Safety assessment criteria generated from candidates that the RAM panel classified as ‘inappropriate’ (I) or
‘necessary to avoid’ (N) (Continued)
91. (N) Patient treated with simvastatin and amiodarone - is prescribed simvastatin > 20 mg/day
C. PATIENT GROUPS PARTICULARLY VULNERABLE TO ADVERSE DRUG EVENTS
ELDERLY PATIENTS
S27 High-risk drug selection in the elderly - Miscellaneous (MS3)
92. (N) Patient aged ≥ 65 with dementia - is prescribed a TCA
93. (N) Patient aged ≥ 65 with dementia but no psychosis - is prescribed an antipsychotic
94. (N) Patient aged ≥ 65 with dementia and psychosis - is prescribed antipsychotic other than risperidone
95. (N) Patient aged ≥ 65 - is prescribed a long acting benzodiazepine
96. (N) Patient aged ≥ 65 with Parkinson’s disease - is prescribed an antipsychotic other than quetiapine or clozapine
97. (N) Patient aged ≥ 65 with Parkinson’s disease - is prescribed a phenothiazine antiemetic
98. (N) Patient aged ≥ 75 - is prescribed a TCA
99. (N) Patient aged ≥ 75 - is prescribed a short acting benzodiazepine
100. (N) Patient aged ≥ 75 - is prescribed a Z-drug
101. (N) Patient aged ≥ 75 - is prescribed an antihistamine with antimuscarinic properties
102. (A) Patient aged ≥ 85 - is prescribed an antispasmodic with antimuscarinic properties
S27 Excess duration - Miscellaneous (MS6)
103. (N) Patient aged ≥ 65 - is prescribed a TCA for ≥ 4 weeks
104. (N) Patient aged ≥ 65 - is prescribed a short acting benzodiazepine for ≥ 4 weeks
105. (N) Patient aged ≥ 65 - is prescribed a Z-drug for ≥ 4 weeks
106. (N) Patient aged ≥ 65 - is prescribed an antispasmodic with antimuscarinic properties for ≥ 4 weeks
107. (N) Patient aged ≥ 65 with dementia and psychosis - is prescribed risperidone for ≥ 12 weeks
108. (N) Patient aged 66 to 75 - is prescribed an antihistamine with antimuscarinic properties for ≥ 4 weeks
109. (N) Patient aged ≥ 75 - is prescribed urologicals with antimuscarinic properties for ≥ 4 weeks
PATIENTS WITH HEART FAILURE
S28 Use in heart failure - Heart failure exacerbation (MS3)
110. (N) Patient with chronic heart failure - is prescribed a class 1 or 3 antiarrhythmics except amiodarone
111. (N) Patient with chronic heart failure - is prescribed verapamil or diltiazem
112. (N) Patient with chronic heart failure - is prescribed minoxidil
113. (N) Patient with chronic heart failure - is prescribed any oral NSAID
114. (N) Patient with chronic heart failure - is prescribed a glitazone
115. (N) Patient with chronic heart failure - is prescribed a tricyclic antidepressant
116. (N) Patient with chronic heart failure - is prescribed itraconazole
117. (N) Patient with chronic heart failure - is prescribed other antifungals (e.g. ketoconazole, fluconazole)
118. (N) Patient with chronic heart failure - is prescribed tadalafil
119. (N) Patient with chronic heart failure - is prescribed disulfiram
CHILDREN AND YOUNG ADULTS
S29 Use in children - Miscellaneous (MS3)
120. (N) Patient aged ≤ 20 - is prescribed a phenothiazine anti-emetic
121. (N) Patient aged ≤ 16 who has no record of Kawasaki disease - is prescribed aspirin
122. (N) Patient aged ≤ 12 - is prescribed a tetracycline
123. (N) Patient aged ≤ 18 - is prescribed an antidepressant other than fluoxetine
124. (I) Patient aged ≤ 18 - is prescribed fluoxetine
The criteria target high-risk use of (A) drugs frequently implicated in PDRM hospital admissions, (B) other drugs implicated in severe PDRM events and (C)
medication use in vulnerable groups. Within each domain A to C, the criteria are organised hierarchically by the high-risk drug (group) that is the focus of each
criterion, followed by safety topic scored in the Delphi study (S) and medication use safety category (MS). MS1 = Indication for risk mitigating drug; MS2 = High
risk drug without compelling indication; MS3 = Drug-disease or Drug-age interaction; MS4 = Drug-Drug interaction (DDI); MS5 = Excessive dose; MS6 = Excessive
duration; MS7 = Prescribing issues linked to patient compliance; MS8 = Inconsistent monitoring
Dreischulte et al. BMC Clinical Pharmacology 2012, 12:5
http://www.biomedcentral.com/1472-6904/12/5
Page 12 of 17
Table 6 Delphi study: Demographics of the 26 panellists, who completed both rounds of ratings
Pharmacists
n = 9 (35%)
General practitioners
n = 17 (65%)
Total
Currently Previously Currently Previously
Works in primary care 7 2 17 - 26 (100%)
Has a prescribing role 2 1 17 - 20 (77%)
Has a strategic role 2 - 1 1 4 (15%)
Mean age in years (SD) 47 (9) 47 (9) 47 (9)
Mean years since training completed (SD) 22 (11) 22 (9) 23 (10)
Mean years of experience of working in primary care (SD) 11 (11) 19 (8) 15 (8)
Table 7 Delphi study priority ratings by the 26 panellists
Topic Median Mean Priority
Accepted as priorities
Quality
Q 16 Not using inhaled corticosteroids in patients with uncontrolled asthma 8 8.0 ++
Q 15 Not using oral anticoagulants in patients with AF and high risk of stroke 8 7.9 ++
Q 11 Not using ACEIs or ARBs in patients with a history of chronic heart failure 8 7.9 ++
Q 14 Not using thrombo-embolic prophylaxis in AF patients at low/moderate risk of stroke 8 7.7 ++
Q 5 Not using ACEIs or ARBs in patients with DM and renal complications 8 7.7 ++
Q 12 Not using beta blockers in patients with a history of chronic heart failure 8 7.7 ++
Q 4 Not using metformin as first line antidiabetic in overweight type 2 diabetics 8 7.6 ++
Q 8 Not using antiplatelets in patients at risk of vascular events 7 7.5 +
Q 6 Not using statins in patients at high risk of cardiovascular events 7 7.4 +
Q 17 Not using bone sparing agents in female patients at high risk of fractures 7 7.3 +
Q 3 Low intensity antidiabetic treatment despite suboptimal HbA1c control 7 7.2 +
Q 10 Not using ACEIs or ARBs in patients with a history of ACS 7 7.0 +
Q 2 Low intensity antihypertensive treatment despite suboptimal BP control 7 6.9 +
Q 9 Not using beta blockers in coronary heart disease 7 6.8 +
Q 7 Underdosing of statins in patients at high risk of cardiovascular events 7 6.7 +
Safety
S 20 Using MTX without taking precautionary action to prevent patient overdosing 9 8.4 ++
S 1 Not using gastro-protection in oral NSAIDs/antiplatelets users at high risk of bleeding 8 8.2 ++
S 3 Using oral NSAIDs in patients at increased risk of renal failure 8 7.9 ++
S 21 Inconsistent monitoring of FBC in patients on DMARDs 8 7.8 ++
S 27 Using sedatives, antipsychotics, anticholinergics in elderly patients 7 7.3 +
S 19 Using bone protection in users of long term oral corticosteroids 7 7.3 +
S 23 Excess duration of female hormones in patients at risk of gynaecological cancer 7 7.3 +
S 10 Excess duration of potassium supplements and potassium sparing diuretics 7 7.2 +
S 28 Using drugs to avoid in patients with heart failure 7 7.1 +
S 18 Excessive dosing of digoxin in patients susceptible to digoxin toxicity 7 7.1 +
S 24 Inconsistent monitoring of thyroid function in patients prescribed amiodarone 7 7.0 +
S 6 Inconsistent monitoring of U&Es in patients at risk of electrolyte imbalance 7 7.0 +
S 14 Co-prescribing beta blockers and rate-limiting calcium channel blockers 7 6.9 +
S 25 Using theophylline in elderly COPD patients without a compelling indication 7 6.9 +
S 15 Using beta blockers in patients with active asthma 7 6.8 +
S 13 Not using of laxatives in strong opioid users 7 6.8 +
S 29 Using drugs to avoid in children and young adults 7 6.7 +
S 5 Using COX II inhibitors in patients at high risk of cardiovascular events 7 6.6 +
S 7 Using thiazide diuretics in patients with a history of CKD 7 6.6 +
S 17 Using long acting sulphonylureas in patients at risk of hypoglycaemia 7 6.6 +
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PDRM from electronic data sources routinely held in
UK primary care. The criteria set targets suboptimal
selection, intensity or omissions of beneficial drug treat-
ments (medication use quality) and high-risk use, incon-
sistent monitoring or patient instructions for drugs
implicated in preventable harm (medication use safety)
in primary care. All items are classified by clinical
importance (appropriateness and necessity) as the out-
put of an extended RAM process. Key professionals in
UK primary care identified eleven clusters of themati-
cally related medication assessment criteria (topics) as
‘high priority’ for quality improvement initiatives. The
three highest rated topics related to methotrexate dosing
instructions, high-risk prescribing of NSAIDs and anti-
platelets and underuse of corticosteroids in asthma.
Development process of the DQIP criteria set
The RAM approach had advantages over the Delphi
technique as an initial step in the criteria development
process, because the face-to-face meeting ensured the
necessary commitment of panellists to place ratings on
an extensive and thematically broad list of candidate cri-
teria that were grounded in the evidence base. The ori-
ginal RAM approach was extended in this study by
introducing the concept of ‘necessary to avoid’, in order
to distinguish between inappropriate (‘not worthwhile’)
and ‘improper’ medication use in safety terms (see table
1). As for the distinction between ‘appropriate’ and
‘necessary’, panellists required examples to apply and
reason the concepts, but the absence of paradoxical
‘appropriateness’ and ‘necessity’ ratings is consistent
with a reliable rating process.
A limitation of consensus methods such the RAM is
that ratings may depend on panel composition [42]. The
chosen panel combined clinical, public health and aca-
demic expertise in primary care medication use in gen-
eral, rather than specialist expertise in the management
of each medical condition covered. It is possible that
generalists underestimate the implications of suboptimal
medication use because they do not individually see
relatively rare PDRM events that have significant impact
at population level. Conversely, specialists tend to over-
estimate the importance of practices that fall within
their own specialty [47,48]. However, since relatively few
candidate criteria (22%) were rejected, it seems unlikely
that including specialists would have substantially
altered the results.
Scope and focus of the DQIP criteria set
Consistent with the intended use of the DQIP criteria
set, our literature search targeted commonly encoun-
tered medical conditions and drug groups implicated in
PDRM events in primary care rather than exclusively
focussing on the elderly. As a consequence, only 27% of
all developed criteria are restricted to patients over 65
years with the majority of generated assessment criteria
covering aspects of medication use which are not or not
exclusively relevant to the elderly [8-10,49], such as pri-
mary prevention of vascular events, use of anti-diabetics
in renal impairment [36] and treatments that are poten-
tially harmful in children [36]. The fact that all topics
identified as ‘high priority’ by the Delphi panel are age
independent additionally underlines the relevance of not
restricting a criteria set to be used in primary care to
the elderly as is the case with many existing criteria sets
[8-10,49].
A limitation of the medication assessment criteria
developed for this study is that several established and
Table 7 Delphi study priority ratings by the 26 panellists (Continued)
S 4 Using COX II inhibitors without compelling indication (low dose aspirin users) 7 6.4 +
S 16 Using metformin in patients with CKD 7 6.4 +
S 26 Excessive dosing of statins in patients on interacting drugs 7 6.3 +
Not scored as priorities for medication improvement
Quality
Q 13 Inadequate dose titration of ACEI, ARBs and BBs in chronic heart failure 6 6.2
Q 1 Not using first line antihypertensives when initiating treatment for high blood pressure 6 6.4
Q 18 Not using calcium/vitamin D supplementation in female elderly patients 6 6.4
Safety
S 2 Using oral NSAIDs in the elderly without compelling indication (no previous trial of full dose paracetamol) 6 6.6
S 9 Using of aldosterone antagonists in patients with a history of CKD 6 6.5
S 11 Co-prescribing anti-infectives with high risk of affecting INR in patients on warfarin 6 6.4
S 12 Using warfarin without a compelling indication in AF with low risk of stroke 6 6.3
S 22 Using HRT in female patients at high risk of cardiovascular events 6 6.2
S 8 Not using allopurinol in thiazide users with a history of gout 6 5.8
Topics are ranked by median scores. Clusters of topics with the same median are ranked in descending order of mean score. Topics with a median of 8 or higher
(’high priority’) are coded ‘++’ and those with a median of 7 (’priority’) ‘+’.
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potentially important criteria were not considered
because the study focused on those that could be
applied routinely to existing UK electronic clinical data.
For example, international normalised ratio (INR)
results in the UK are often held in bespoke systems
which hinder the implementation of meaningful mea-
sures for monitoring anticoagulant use [1-4]. Similarly,
although a broad spectrum of medication use categories
are covered, the criteria set is mainly focussed on the
prescribing and monitoring stages of the medication use
process with minimal coverage of patient education and
compliance. In the future, the increasing sophistication
of clinical information systems and the ability to link
clinical datasets with laboratory systems and dispensing
data would make an even broader set of assessment cri-
teria feasible.
Although the DQIP criteria set has been developed for
application in UK primary care, the drug groups
reported to be implicated in PDRM events in primary
care are similar internationally [50-52], and we would
expect the areas focused on to be relevant in other
countries and health care settings. Nevertheless, some
local adaptation may be required in order to account for
differences in drug licensing, available resources, and
clinical guidelines.
Implications for quality improvement initiatives
The Delphi approach allowed stakeholders in primary
care to prioritise the chosen medication use topics for
improvement initiatives in UK primary care. The Delphi
panel was deliberately chosen to include both day to day
prescribers (GPs do almost all primary care prescribing,
especially of the more complex kind being assessed in
this study, but pharmacists prescribe for some patients
and conditions) and those involved in prescribing gov-
ernance and improvement (predominately pharmacists
but including GPs with a more strategic role). A limita-
tion is that our focus on professionals involved in pri-
mary care prescribing meant that we did not seek to
include either specialist or patient/public perspectives in
the Delphi panel. Since there is evidence that practi-
tioners’ perceptions of a targeted behaviour as meaning-
ful is a pre-requisite to changing behaviour [53] we
aimed to identify medication improvement topics which
met this condition to inform the design of an interven-
tion targeting primary care professionals.
It is important to note that even those topics that were
not considered to be priorities (3 quality - and 6 safety
topics) contain individual criteria that were agreed to be
‘necessary’ to do or avoid by the RAM panel. Examples
are ‘inadequate dose titration of ACEI, ARBs and beta
blockers in chronic heart failure’, and the ‘using of war-
farin without a compelling indication in atrial fibrillation
with low risk of stroke’. These should therefore not be
neglected. Lower priority ratings nevertheless indicate
that changing and improving the corresponding medica-
tion use aspects may require targeted effort (or
resources) in order to influence prescribing behaviour.
Conclusions
The DQIP medication assessment criteria set presented
here has been developed using established consensus
methods and complements existing medication assess-
ment instruments by not being limited to the elderly and
by targeting a wide spectrum of medication use practices
implicated in common and/or severe PDRM events in
primary care. As all previously published explicit medica-
tion assessment tools, the criteria set presented here does
not, however, provide comprehensive coverage of all
situations that put patients at risk of PDRM, reflecting
the large scope and high complexity of medication use in
primary care and the limitations of current UK clinical
information systems. The best choice of criteria set will
therefore depend on the main purpose to be addressed
and will be guided by local priorities. Informed by the
priority ratings of a panel of UK primary care profes-
sionals, we have selected a subset of the DQIP criteria to
serve as outcome measures in a cluster randomised trial
evaluating the effectiveness of a complex intervention to
improve prescribing safety (Trial registration number
NCT01425502).
The DQIP criteria were primarily developed to facili-
tate the identification of patients at risk of PDRM from
routine electronic data sets for a targeted review of their
medication. However, we anticipate that they could also
serve a range of other purposes, for example by inform-
ing the design of clinical decision support systems,
where the classification of criteria by ‘appropriateness’
and ‘necessity’ may guide the selection of alerts that
should or should not be interruptive to clinicians’ work-
flow. Performance feedback is a further potential appli-
cation, but in order not to overwhelm practitioners, the
developed criteria are likely to require further prioritisa-
tion and/or the design of meaningful composites, for
example by aggregating items that address the same
topic [54] or medication use category [13].
An inherent limitation of explicit assessment criteria is
that they cannot fully account for clinical factors that
may justify deviations from what is considered to be
best practice in an ‘average’ patient. The extent to which
patients identified to be at risk of PDRM are judged by
practitioners to represent actual opportunities for
improvement (concurrent validity) and the extent to
which any improvements in prescribing or monitoring
translate into improved patient outcomes (predictive
validity) therefore deserve further study.
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